Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease

被引:41
|
作者
Cales, Paul [1 ,2 ]
Boursier, Jerome [1 ,2 ]
Chaigneau, Julien [2 ]
Laine, Fabrice [3 ,4 ]
Sandrini, Jeremy [5 ]
Michalak, Sophie [2 ,5 ]
Hubert, Isabelle [1 ,2 ]
Dib, Nina [1 ,2 ]
Oberti, Frederic [1 ,2 ]
Bertrais, Sandrine [2 ]
Hunault, Gilles [2 ]
Cavaro-Menard, Christine [6 ]
Gallois, Yves [7 ]
Deugnier, Yves [3 ,4 ]
Rousselet, Marie C. [2 ,5 ]
机构
[1] CHU Angers, Serv Hepatogastroenterol, F-49933 Angers 09, France
[2] Univ Angers, PRES UNAM, Lab HIFIH, Angers, France
[3] CHU, Hop Pontchaillou, INSERM, CIC 0203, Rennes, France
[4] CHU, Hop Pontchaillou, Serv Malad Foie, Rennes, France
[5] CHU Angers, Dept Pathol Cellulaire & Tissulaire, F-49933 Angers 09, France
[6] Univ Angers, PRES UNAM, Lab Ingn Syst Automatises, Angers, France
[7] CHU Angers, Lab Biochim & Biol Mol, F-49933 Angers 09, France
关键词
area of fibrosis; blood test; fractal dimension; image analysis; liver biopsy; liver fibrosis; metabolic syndrome NAFLD; LOGISTIC-REGRESSION; IMAGE-ANALYSIS; ACCURACY; MODELS; VARIABILITY; VALIDATION; BIOPSY; SYSTEM; NAFLD;
D O I
10.1111/j.1478-3231.2010.02314.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: Our aim was to develop an accurate, non-invasive, blood-test-based method for identifying the main characteristics of liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Methods: Fibrosis was staged according to NASH-CRN and Metavir systems in 226 patients with NAFLD. A fully automated algorithm measured the fractal dimension (FD) and the area of fibrosis (AOF). Independent predictors of diagnostic targets were determined using bootstrap methods. Results: (i) Development. Significant fibrosis defined by NASH-CRN F >= 2 was diagnosed by weight, glycaemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and prothrombin index [area under the receiver operating characteristic (AUROC) = 0.867]; significant fibrosis defined by Metavir F >= 2 was diagnosed by weight, age, glycaemia, AST, ALT, ferritin and platelets (FibroMeter AUROC = 0.941, P < 0.005). AOF was estimated by the combination of hyaluronic acid, glycaemia, AST, ALT, platelets and prothrombin index (R-a(2) = 0.530), while FD was estimated by hyaluronic acid, glycaemia, AST/ALT, weight and platelets (R-a(2) = 0.529). (ii) Evaluation. Although NASH-CRN was a better system for fibrosis staging, Metavir staging was a better reference for blood test. Thus, the patient rate with predictive values >= 90% by tests was 97.3% with Metavir reference vs. 66.5% with NASH-CRN reference (P < 10(-3)). FibroMeter showed a significantly higher AUROC than the NAFLD fibrosis score for significant fibrosis, but not for severe fibrosis or cirrhosis, with both staging systems. Relationships between fibrosis lesions were well reflected by blood tests, e. g., the correlation between histological area and FD of fibrosis (r(s) = 0.971, P < 10(-3)) was well reflected by the relationship between respective blood tests (rs = 0.852, P < 10(-3)). Conclusions: Different characteristics of fibrosis in NAFLD can be diagnosed and quantified by blood tests with excellent accuracy.
引用
收藏
页码:1346 / 1354
页数:9
相关论文
共 50 条
  • [21] Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease
    Inadomi, Chika
    Takahashi, Hirokazu
    Ogawa, Yuji
    Oeda, Satoshi
    Imajo, Kento
    Kubotsu, Yoshihito
    Tanaka, Kenichi
    Kessoku, Takaomi
    Okada, Michiaki
    Isoda, Hiroshi
    Akiyama, Takumi
    Fukushima, Hideaki
    Yoneda, Masato
    Anzai, Keizo
    Aishima, Shinichi
    Nakajima, Atsushi
    Eguchi, Yuichiro
    HEPATOLOGY RESEARCH, 2020, 50 (06) : 682 - 692
  • [22] Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease
    Arteaga, Ingrid
    Buezo, Isabel
    Exposito, Carmen
    Pera, Guillem
    Rodriguez, Lluis
    Aluma, Alba
    Antonia Auladell, M.
    Toran, Pere
    Caballeria, Llorenc
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2014, 37 (09): : 503 - 510
  • [23] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Hannele Yki-Järvinen
    Diabetologia, 2016, 59 : 1104 - 1111
  • [24] Diagnosis and management of non-alcoholic fatty liver disease
    Jennison, Erica
    Patel, Janisha
    Scorletti, Eleonora
    Byrne, Christopher D.
    POSTGRADUATE MEDICAL JOURNAL, 2019, 95 (1124) : 314 - 322
  • [25] The diagnosis and treatment of non-alcoholic fatty liver disease
    Altinbas, A.
    Sowa, J. -P.
    Hasenberg, T.
    Canbay, A.
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2015, 61 (03) : 159 - 169
  • [26] Non-alcoholic fatty liver disease: The diagnosis and management
    Abd El-Kader, Shehab M.
    El-Den Ashmawy, Eman M. Salah
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (06) : 846 - 858
  • [27] Non-alcoholic fatty liver disease: The diagnosis and management
    Shehab M Abd El-Kader
    Eman M Salah El-Den Ashmawy
    World Journal of Hepatology, 2015, 7 (06) : 846 - 858
  • [28] Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation
    Nascimbeni, Fabio
    Loria, Paola
    Ratziu, Vlad
    DIGESTIVE DISEASES, 2014, 32 (05) : 586 - 596
  • [29] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Yki-Jarvinen, Hannele
    DIABETOLOGIA, 2016, 59 (06) : 1104 - 1111
  • [30] Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2018, 38 : 64 - 66